francesco_granata

Circassia appoints new chairman from Biogen Idec

pharmafile | September 26, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen IDEC, Circassia, granata 

Speciality biopharma firm Circassia has appointed Dr Francesco Granata as its non-executive chairman. 

Granata is executive in Residence at Warburg Pincus, following a career of over 30 years in the pharma industry. Most recently Granata was executive VP at Biogen Idec with responsibility for the firm’s commercial and medical affairs operations, and a Board member of the EFPIA.

“I am excited to join Circassia at this important time in the company’s development,” said Granata. Steve Harris, Circassia’s chief executive and co-founder added: “I am delighted Francesco has chosen to join Circassia as chairman. His extensive international commercial and R&D experience will prove invaluable as we continue the company’s rapid development into a leading allergy business.”

Before his recent role at Biogen Idec Granata was the Group VP and president responsible for Canada and major European markets at Schering-Plough. Prior to this, he was Regional president for Northern Europe at Pfizer, following a period as the company’s president of the Middle East and Africa region. 

Related Content

shutterstock_138095450

Circassia terminates AstraZeneca partnership in exchange for £150m debt settlement

Circassia Pharmaceuticals has announced its decision to break away from a partnership it forged with …

12324594465_18434550d7_z

Circassia stumbles with allergy treatments at clinical trial stage, again

Circassia has slumped at the Phase 2 clinical trial stage again, after its failure with …

Biogen to build billion-dollar plant in Switzerland

Biogen plans to open a $1 billion manufacturing facility in Switzerland, to help Europe deal …

Latest content